Otsuka Holdings Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
7.9M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.4M | +0.16% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.1M | +2.69% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.0M | -0.64% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
1.6M | +1.65% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
1.5M | -1.49% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Aristotle Capital Management, LLC
|
1.3M | -1.02% | |
|
Pacer Advisors, Inc.
|
188.0K | -3.90% | |
|
Paradigm Asset Management Company, LLC
|
20.0K | +1.00% |
Dividend History 3Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥140 | +16.7% |
| 2024 | ¥120 | +9.1% |
| 2023 | ¥110 | +10.0% |
| 2022 | ¥100 | 0.0% |
| 2021 | ¥100 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,498,276M | ¥1,737,998M | ¥2,018,568M | ¥2,329,861M |
| Gross Profit | ¥1,003,245M | ¥1,168,496M | ¥1,407,348M | ¥1,669,428M |
| Operating Income | ¥152,469M | ¥186,064M | ¥291,668M | ¥415,992M |
| Pretax Income | ¥168,478M | ¥179,017M | ¥149,178M | ¥344,645M |
| Net Income | ¥125,463M | ¥133,906M | ¥121,616M | ¥343,120M |
| EPS | ¥231.15 | ¥246.78 | ¥224.10 | ¥633.76 |
| Operating Margin | 10.18% | 10.71% | 14.45% | 17.85% |
| Balance Sheet | ||||
| Total Assets | ¥2,820,915M | ¥3,102,638M | ¥3,361,244M | ¥3,739,251M |
| Total Equity | ¥2,010,994M | ¥2,225,255M | ¥2,393,683M | ¥2,733,580M |
| Total Liabilities | ¥809,921M | ¥877,383M | ¥967,561M | ¥1,005,671M |
| Cash | ¥410,684M | ¥471,634M | ¥513,341M | ¥426,173M |
| Interest-bearing Debt | ¥212,453M | ¥194,161M | ¥214,187M | ¥189,383M |
| Equity Ratio | 71.29% | 71.72% | 71.21% | 73.11% |
| D/E Ratio | 0.11 | 0.09 | 0.09 | 0.07 |
| Cash Flow | ||||
| Operating CF | ¥228,864M | ¥211,848M | ¥283,232M | ¥354,638M |
| Investing CF | -¥95,288M | -¥81,575M | -¥190,538M | -¥265,793M |
| Financing CF | -¥95,844M | -¥95,474M | -¥60,260M | -¥189,367M |
| Free CF | ¥115,712M | ¥104,061M | ¥168,559M | ¥225,276M |
| Efficiency | ||||
| ROE | 6.24% | 6.02% | 5.08% | 12.55% |
| ROA | 4.45% | 4.32% | 3.62% | 9.18% |
Latest IR Information
-
Notice Regarding the Status of Treasury Stock Acquisition
From February 16 to February 27, 2026, we acquired 312,900 shares of our common stock through market purchases at a total amount of 3,295,727,500 yen.
Read more -
Notice Regarding Differences in Individual Performance Compared to the Previous Fiscal Year
For the fiscal year ending December 2025, operating revenue was 98,840 million yen, a 16.3% decrease year-over-year, operating income was 82,674 million yen, down 19.7%, and net income attributable to owners of parent was 89,863 million yen, down 15.5%.
Read more -
Notice of Decision Regarding Share Buyback and Cancellation of Treasury Stock
Otsuka Holdings plans to acquire up to 7,000,000 shares of treasury stock (ceiling, 1.33% of total issued shares) for a maximum of 50 billion yen from February 16, 2026 to December 23, 2026, with cancellation scheduled on January 29, 2027.
Read more -
Approach and Policy on the Reduction of Trading Unit
Otsuka Holdings recognizes that reducing the trading unit is effective in encouraging retail investor participation in the market and has expressed a policy to carefully consider this matter in light of future stock market trends and stock price levels.
Read more -
Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)
For the fiscal year ending December 2025, consolidated revenue was JPY 2,468.892 billion (6.0% YoY increase), operating income was JPY 479.375 billion (48.2% YoY increase), and net income attributable to owners of parent was JPY 363.150 billion (5.8% YoY increase).
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥10,850
Rating Score: 1.92 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, the company offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Tokyo, Japan.